These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36289363)

  • 1. Is esaxerenone the ultimate mineralocorticoid receptor antagonist?
    Hoshide S
    Hypertens Res; 2023 Feb; 46(2):516-517. PubMed ID: 36289363
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.
    Bhuiyan AS; Rafiq K; Kobara H; Masaki T; Nakano D; Nishiyama A
    Hypertens Res; 2019 Jun; 42(6):892-902. PubMed ID: 30664703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
    Li L; Guan Y; Kobori H; Morishita A; Kobara H; Masaki T; Nakano D; Nishiyama A
    Hypertens Res; 2019 Jun; 42(6):769-778. PubMed ID: 30587856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).
    Takahashi M; Ubukata O; Homma T; Asoh Y; Honzumi M; Hayashi N; Saito K; Tsuruoka H; Aoki K; Hanzawa H
    FEBS Lett; 2020 May; 594(10):1615-1623. PubMed ID: 31991486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review.
    Janković SM; Janković SV
    Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):291-308. PubMed ID: 35190999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
    Arai K; Morikawa Y; Ubukata N; Sugimoto K
    Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esaxerenone: First Global Approval.
    Duggan S
    Drugs; 2019 Mar; 79(4):477-481. PubMed ID: 30806972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of esaxerenone, a nonsteroidal mineralocorticoid receptor blocker, independent of urinary sodium/potassium ratio and salt intake.
    Morimoto S; Ichihara A
    Hypertens Res; 2024 Apr; 47(4):970-971. PubMed ID: 38273001
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.
    Ito S; Itoh H; Rakugi H; Okuda Y; Yamakawa S
    J Hum Hypertens; 2019 Jul; 33(7):542-551. PubMed ID: 31113987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro
    Yamakawa S; Homma T; Yamada M; Igawa Y; Yoshimura M
    Nihon Yakurigaku Zasshi; 2020; 155(5):340-350. PubMed ID: 32879177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease.
    Wan N; Rahman A; Nishiyama A
    J Hum Hypertens; 2021 Feb; 35(2):148-156. PubMed ID: 32661269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
    Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
    Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
    Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Metabolism, and Excretion of [
    Yamada M; Mendell J; Takakusa H; Shimizu T; Ando O
    Drug Metab Dispos; 2019 Mar; 47(3):340-349. PubMed ID: 30541878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
    Arai K; Tsuruoka H; Homma T
    Eur J Pharmacol; 2015 Dec; 769():266-73. PubMed ID: 26607463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction.
    Ito S; Itoh H; Rakugi H; Okuda Y; Iijima S
    Hypertens Res; 2021 May; 44(5):489-497. PubMed ID: 33323991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E; White WB; Bakris G
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Will esaxerenone be added to the antihypertensive treatment strategy of practicing physicians as a second-line antihypertensive drug?
    Yoshida T
    Hypertens Res; 2024 Sep; 47(9):2574-2576. PubMed ID: 39232192
    [No Abstract]   [Full Text] [Related]  

  • 19. Exposure-response analysis of the efficacy and safety of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with or without diabetic kidney disease.
    Yoshihara K; Fukae M; Kastrissios H; Wada R; Shimizu T
    Drug Metab Pharmacokinet; 2024 Apr; 55():100535. PubMed ID: 38245949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study.
    Iwahana T; Saito Y; Okada S; Kato H; Ono R; Kobayashi Y
    PLoS One; 2021; 16(11):e0259485. PubMed ID: 34748605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.